Y
Yotam Bronstein
Researcher at Tel Aviv University
Publications - 13
Citations - 590
Yotam Bronstein is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 4 publications receiving 167 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia.
Yair Herishanu,Irit Avivi,Anat Amit Aharon,Gabi Shefer,Shai Levi,Yotam Bronstein,Miguel Morales,Tomer Ziv,Yamit Shorer Arbel,Lydia Scarfò,Erel Joffe,Chava Perry,Paolo Ghia +12 more
TL;DR: In this article, the authors evaluated humoral immune responses to the BNT162b2 mRNA COVID-19 vaccine in patients with CLL and compared responses with those obtained in age-matched healthy control subjects.
Journal ArticleDOI
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Avishay Spitzer,Yoel Angel,Or Marudi,David Zeltser,E Saiag,Hanoch Goldshmidt,Ilana Goldiner,Moshe Stark,Ora Halutz,Ronni Gamzu,M. Slobodkin,Nadav Amrami,Eugene Feigin,Meital Elbaz,Moran Furman,Yotam Bronstein,Amanda Chikly,Anna Eshkol,Victoria Furer,Talia Mayer,Suzy E Meijer,Ariel Melloul,Michal Mizrahi,M. V. Yakubovsky,Dana Rosenberg,Ari Safir,Liron Spitzer,Eyal Taleb,Ori Elkayam,Adi Silberman,Tali Eviatar,Ofir Elalouf,Tal Levinson,Katia Pozyuchenko,Ayelet Itzhaki-Alfia,Elliot Sprecher,Ronen Ben-Ami,Oryan Henig +37 more
TL;DR: Among health care workers at a single center in Israel who were previously vaccinated with a 2-dose series of BNT162b2, administration of a booster dose compared with not receiving one was associated with a significantly lower rate of SARS-CoV-2 infection over a median of 39 days of follow-up.
Journal ArticleDOI
Six Months Antibody Persistence after BNT162b2 mRNA COVID-19 Vaccination in Patients with Chronic Lymphocytic Leukemia.
Yair Herishanu,Irit Avivi,Shai Levi,Gabi Shefer,Yotam Bronstein,Miguel Morales Moshiashvili,Tomer Ziv-Baran,Lydia Scarfò,Chava Perry,Paolo Ghia +9 more
Journal ArticleDOI
COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge
Yotam Bronstein,Roi Gat,S Levi,Yael C Cohen,Efrat Luttwak,Noam Benyamini,Tamir Shragai,Roy Vitkon,Miriam Neaman,Nili Eilaty,Mor Levi,Svetlana Trestman,Chava Perry,Yair Herishanu,Irit Avivi +14 more
TL;DR: Christensen et al. as discussed by the authors reported the clinical outcome of 131 hematologic patients with lymphoproliferative diseases, infected with SARS-CoV-2 during the Omicron surge in Israel, between January and March 2022.
Journal ArticleDOI
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
Yamit Shorer Arbel,Ben-Zion Katz,Ben-Zion Katz,Ronen Gabizon,Amit Shraga,Yotam Bronstein,Talia Kamdjou,Anat Levin,Chava Perry,Chava Perry,Irit Avivi,Irit Avivi,Nir London,Yair Herishanu,Yair Herishanu +14 more
TL;DR: In this paper, the Bruton's tyrosine kinase (BTK) PROTAC compounds were used to degrade the BTK degradation in chronic lymphocytic leukemia (CLL) cells.